International Stem Cell Corp. (ISCO) Faces Huge Therapeutic Market
International Stem Cell Corp., developers of human parthenogenic stem cells (hpSCs), a new class of non-embryonic stem cells that has the best characteristics of each of the other classes of stem cells, is focused on using hpSCs to treat severe diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe, immune-matched human cells. Parthenogenic stem cells hold great promise for stem cell regenerative medicine by addressing the critical issue of immune-rejection, the problem of finding cells that have the right chemical structure so as not…